Biosimilar of Forteo launched in Japan by Mochida
Strides' Stelis Moves Closer To EU Nod For Forteo Biosimilar In FY23 :: Scrip
EMA recommends approval of teriparatide and pegfilgrastim biosimilars
Amphastar's Forteo ANDA Hit With CRL As Wait Goes On :: Generics Bulletin
Are new bone drugs from Amgen and Radius cost-effective? Not even close, ICER says | Fierce Pharma
Pfenex Pitches Teriparatide Pen Against Lilly's Forteo as Partner Alvogen Files In Europe :: Generics Bulletin
Biosimilars Law Bulletin | Rothwell Figg | Biologics and Biosimilars Practice
Biosimilar Market Size, Share, Industry Analysis, & Forecast 2029
Bevacizumab and teriparatide biosimilars launched in Japan
Biosimilar Therapeutic Peptides Market Size, Trends and Global Forecast To 2032
Alvogen inks deals for Forteo biosimilar in South Korea, Israel and Ca
Biosimilar drugs: Approved products in the EU and US continuing to grow
Top developments in biosimilars during 2019 - GaBI Journal
Biosimilars Law Bulletin | Rothwell Figg | Biologics and Biosimilars Practice
ROVI will market TEVA's osteoporosis treatment for adults Tetridar ® ( teriparatide) in Spain
Biosimilar Hormones Market Size, Trends and Global Forecast To 2032
Canada approves three teriparatide biosimilars in 2020
Australian and Indian approval for teriparatide products
EX-99.1
Biosimilars Law Bulletin | Rothwell Figg | Biologics and Biosimilars Practice
Teva Identifies Teriparatide Importance Amid US Launch Drought :: Generics Bulletin
Pfenex: The First U.S. Forteo Biosim And A Host Of Other Biosims In Pipeline (NYSEMKT:PFNX) | Seeking Alpha
Opportunities and Challenges in Biosimilar Development - BioProcess InternationalBioProcess International
Global osteoporosis market to reach $11.2bn by 2027 - Pharmaceutical Technology
